Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$4.58
+0.24 (+5.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-54.5M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$846M
P/E
N/A
•EV/EBITDA
188.0x
↑ROE
-11.2%
↓Gross Margin
154.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+132.9%
FCF CAGR
—
FCF margin
-72.5%
FCF / Net income
2.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $36.1M · net income $-11.4M · FCF $-26.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36.1M | $36.1M | $24.4M | $29.3M | $2.9M |
| Net Income | $-11.4M | $-11.4M | $-24.9M | $-76.4M | $-58.6M |
| EBITDA | $4.2M | $4.2M | $-13.7M | $-16.2M | $-47.5M |
| EPS | -0.07 | -0.07 | -0.18 | -1.09 | -1.16 |
| Gross Margin | 154.7% | 154.7% | 191.7% | 201.7% | 950.0% |
| Operating Margin | -23.0% | -23.0% | -108.3% | -260.3% | -2038.5% |
| Net Margin | -31.5% | -31.5% | -102.2% | -260.5% | -2047.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.05 | 0.04 | 0.06 |
| Current Ratio | 2.06 | 2.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.2M | $-26.2M | $-54.5M | $-76.9M | $-43.3M |
| Returns | |||||
| ROE | -11.2% | -11.2% | -35.1% | -79.7% | -53.7% |
| Valuation | |||||
| EV/EBITDA | 187.95 | 187.95 | — | — | — |
| P/B | 8.11 | 8.11 | 4.53 | 0.99 | 1.64 |
| Growth & Yield | |||||
| Revenue Growth | 48.4% | 48.4% | -16.9% | 925.4% | — |
| EPS Growth | 61.1% | 61.1% | 83.5% | 6.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+133.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → -0.07
Residual
+133.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.